Literature DB >> 29198240

Aligning the ICD-11 classification of disorders due to substance use with global service needs.

V Poznyak1, G M Reed1, M E Medina-Mora2.   

Abstract

The use of psychoactive, potentially dependence-producing substances is highly prevalent around the world, and contributes substantially to global disease burden. There is a major gap between the need for treatment for substance use disorders. Changes proposed for the classification of substance use disorders in the Eleventh Revision of the International Classification of Diseases and Related Health Problems, based on a public health approach, have important implications for the conceptualisation, structure and availability of services. These include: (1) an updated and expanded range of substance classes; (2) greater specification of different harmful patterns of substance use, which may be continuous or episodic and recurrent; (3) a new category to denote single episodes of harmful use; (4) a category describing hazardous use of substances; and (5) simplification of diagnostic guidelines for substance dependence. This paper describes these changes and the opportunities they present for improved prevention, treatment, monitoring and health policy.

Entities:  

Keywords:  Classification; ICD-11; substance abuse; substance use disorders; treatment

Mesh:

Year:  2017        PMID: 29198240      PMCID: PMC6998967          DOI: 10.1017/S2045796017000622

Source DB:  PubMed          Journal:  Epidemiol Psychiatr Sci        ISSN: 2045-7960            Impact factor:   6.892


  17 in total

1.  THE UNTILLED FIELDS OF PUBLIC HEALTH.

Authors:  C E Winslow
Journal:  Science       Date:  1920-01-09       Impact factor: 47.728

Review 2.  Reduced-risk drinking as a viable treatment goal in problematic alcohol use and alcohol dependence.

Authors:  Jan van Amsterdam; Wim van den Brink
Journal:  J Psychopharmacol       Date:  2013-07-02       Impact factor: 4.153

3.  A conceptual framework for the revision of the ICD-10 classification of mental and behavioural disorders.

Authors: 
Journal:  World Psychiatry       Date:  2011-06       Impact factor: 49.548

4.  Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys.

Authors:  Philip S Wang; Sergio Aguilar-Gaxiola; Jordi Alonso; Matthias C Angermeyer; Guilherme Borges; Evelyn J Bromet; Ronny Bruffaerts; Giovanni de Girolamo; Ron de Graaf; Oye Gureje; Josep Maria Haro; Elie G Karam; Ronald C Kessler; Viviane Kovess; Michael C Lane; Sing Lee; Daphna Levinson; Yutaka Ono; Maria Petukhova; José Posada-Villa; Soraya Seedat; J Elisabeth Wells
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

5.  Online survey characterizing vaporizer use among cannabis users.

Authors:  Dustin C Lee; Benjamin S Crosier; Jacob T Borodovsky; James D Sargent; Alan J Budney
Journal:  Drug Alcohol Depend       Date:  2015-12-30       Impact factor: 4.492

6.  Relapse to opioid use in opioid-dependent individuals released from compulsory drug detention centres compared with those from voluntary methadone treatment centres in Malaysia: a two-arm, prospective observational study.

Authors:  Martin P Wegman; Frederick L Altice; Sangeeth Kaur; Vanesa Rajandaran; Sutayut Osornprasop; David Wilson; David P Wilson; Adeeba Kamarulzaman
Journal:  Lancet Glob Health       Date:  2016-12-08       Impact factor: 26.763

7.  'Vaping' profiles and preferences: an online survey of electronic cigarette users.

Authors:  Lynne Dawkins; John Turner; Amanda Roberts; Kirstie Soar
Journal:  Addiction       Date:  2013-03-28       Impact factor: 6.526

8.  Delay and failure in treatment seeking after first onset of mental disorders in the World Health Organization's World Mental Health Survey Initiative.

Authors:  Philip S Wang; Matthias Angermeyer; Guilherme Borges; Ronny Bruffaerts; Wai Tat Chiu; Giovanni DE Girolamo; John Fayyad; Oye Gureje; Josep Maria Haro; Yueqin Huang; Ronald C Kessler; Viviane Kovess; Daphna Levinson; Yoshibumi Nakane; Mark A Oakley Brown; Johan H Ormel; José Posada-Villa; Sergio Aguilar-Gaxiola; Jordi Alonso; Sing Lee; Steven Heeringa; Beth-Ellen Pennell; Somnath Chatterji; T Bedirhan Ustün
Journal:  World Psychiatry       Date:  2007-10       Impact factor: 49.548

9.  Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet       Date:  2016-10-08       Impact factor: 79.321

10.  Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: mathematical modelling study.

Authors:  Dan Chisholm; Shekhar Saxena
Journal:  BMJ       Date:  2012-03-02
View more
  11 in total

Review 1.  How deaths can help clinicians and policy-makers understand the risks of novel psychoactive substances.

Authors:  John Martin Corkery; Fabrizio Schifano; Giovanni Martinotti
Journal:  Br J Clin Pharmacol       Date:  2020-01-14       Impact factor: 4.335

2.  ICD-11 chapter on mental and behavioural disorders: heralding new ways of seeing old problems.

Authors:  O Gureje
Journal:  Epidemiol Psychiatr Sci       Date:  2018-06       Impact factor: 6.892

3.  An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5.

Authors:  Michael B First; Wolfgang Gaebel; Mario Maj; Dan J Stein; Cary S Kogan; John B Saunders; Vladimir B Poznyak; Oye Gureje; Roberto Lewis-Fernández; Andreas Maercker; Chris R Brewin; Marylene Cloitre; Angelica Claudino; Kathleen M Pike; Gillian Baird; David Skuse; Richard B Krueger; Peer Briken; Jeffrey D Burke; John E Lochman; Spencer C Evans; Douglas W Woods; Geoffrey M Reed
Journal:  World Psychiatry       Date:  2021-02       Impact factor: 49.548

4.  Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders.

Authors:  Geoffrey M Reed; Michael B First; Cary S Kogan; Steven E Hyman; Oye Gureje; Wolfgang Gaebel; Mario Maj; Dan J Stein; Andreas Maercker; Peter Tyrer; Angelica Claudino; Elena Garralda; Luis Salvador-Carulla; Rajat Ray; John B Saunders; Tarun Dua; Vladimir Poznyak; María Elena Medina-Mora; Kathleen M Pike; José L Ayuso-Mateos; Shigenobu Kanba; Jared W Keeley; Brigitte Khoury; Valery N Krasnov; Maya Kulygina; Anne M Lovell; Jair de Jesus Mari; Toshimasa Maruta; Chihiro Matsumoto; Tahilia J Rebello; Michael C Roberts; Rebeca Robles; Pratap Sharan; Min Zhao; Assen Jablensky; Pichet Udomratn; Afarin Rahimi-Movaghar; Per-Anders Rydelius; Sabine Bährer-Kohler; Ann D Watts; Shekhar Saxena
Journal:  World Psychiatry       Date:  2019-02       Impact factor: 49.548

5.  Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?

Authors:  John Marsden; Betty Tai; Robert Ali; Lian Hu; A John Rush; Nora Volkow
Journal:  Addiction       Date:  2019-01-30       Impact factor: 6.526

Review 6.  Advances in the science and treatment of alcohol use disorder.

Authors:  K Witkiewitz; R Z Litten; L Leggio
Journal:  Sci Adv       Date:  2019-09-25       Impact factor: 14.136

7.  ICD-11 for Alcohol Use Disorders: Not a Convincing Answer to the Challenges.

Authors:  Jürgen Rehm; Markus Heilig; Antoni Gual
Journal:  Alcohol Clin Exp Res       Date:  2019-09-05       Impact factor: 3.455

8.  Leveraging Shannon Entropy to Validate the Transition between ICD-10 and ICD-11.

Authors:  Donghua Chen; Runtong Zhang; Xiaomin Zhu
Journal:  Entropy (Basel)       Date:  2018-10-08       Impact factor: 2.524

9.  Single episode of alcohol use resulting in injury: a cross-sectional study in 21 countries.

Authors:  Cheryl J Cherpitel; Yu Ye; Vladimir Poznyak
Journal:  Bull World Health Organ       Date:  2018-03-20       Impact factor: 9.408

10.  A Bibliometric Analysis of the Development of ICD-11 in Medical Informatics.

Authors:  Donghua Chen; Runtong Zhang; Hongmei Zhao; Jiayi Feng
Journal:  J Healthc Eng       Date:  2019-12-25       Impact factor: 2.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.